Carisma Therapeutics, Inc. (CARM)
Automate Your Wheel Strategy on CARM
With Tiblio's Option Bot, you can configure your own wheel strategy including CARM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CARM
- Rev/Share 0.2577
- Book/Share -1.1009
- PB -0.0391
- Debt/Equity -0.037
- CurrentRatio 0.4799
- ROIC 15.9775
- MktCap 1796171.0
- FreeCF/Share -0.8936
- PFCF -0.0481
- PE -0.0364
- Debt/Assets 0.3392
- DivYield 0
- ROE 1.6229
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CARM | Robert W. Baird | Outperform | Neutral | $10 | $1 | Dec. 12, 2024 |
| Downgrade | CARM | BTIG Research | Buy | Neutral | -- | -- | Dec. 10, 2024 |
News
Carisma Announces Delisting from Nasdaq and SEC Deregistration
Published: December 05, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market LLC ("Nasdaq") and the deregistration of its common stock in order to suspend and ultimately terminate the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). As previously reported, as a result of the Company's previously disclosed noncompliance with the bid price, market value of listed securities, and market …
Read More
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE and CARM on Behalf of Shareholders
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 23, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Couchbase, Inc. (NASDAQ: BASE)'s sale to Haveli Investments for $24.50 per share in cash. If you are a Couchbase shareholder, click here to learn more about your legal rights and options.
Read More
About Carisma Therapeutics, Inc. (CARM)
- IPO Date 2014-02-06
- Website https://carismatx.com
- Industry Biotechnology
- CEO Saar Gill
- Employees 46